Serelaxin bei akuter Herzinsuffizienz Serelaxin bei der akuten Herzinsuffizienz: Wieder ein negatives Ergebnis Effects of serelaxin in patients with acute heart failure. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg...
More
Serelaxin bei akuter Herzinsuffizienz Serelaxin bei der akuten Herzinsuffizienz: Wieder ein negatives Ergebnis Effects of serelaxin in patients with acute heart failure. Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, et al. N Engl J Med 2019; 381:716-726 BACKGROUND: Serelaxin is a recombinant form of human re- to-treat analysis. At day 180, death from cardiovascular causes had laxin-2, a vasodilator hormone that contributes to cardiovascular and occurred in 285 of the 3274 patients (8.7%) in the serelaxin group renal adaptations during pregnancy. Previous studies have suggested and in 290 of the 3271 patients (8.9%) in the placebo group (hazard that treatment with serelaxin may result in relief of symptoms and in ratio, 0.98; 95% confidence interval [CI], 0.83 to 1.15; P = 0.77). At better outcomes in patients with acute heart failure. day 5, worsening heart failure had occurred in 227 patients (6.9%) METHODS: In this multicenter, dou
Less
